Professor Kim Tieu
Biomedical Research - Translational & Stratified Medicine (Peninsula Schools of Medicine and Dentistry)
2016-present ║ Professor ║ Plymouth University Peninsula Schools of Medicine and Dentistry.
2013-2015 ║ Associate Professor (Reader) ║ Plymouth University Peninsula Schools of Medicine and Dentistry.
2013-present ║ Adjunct Faculty ║ University of Rochester(Rochester, New York).
2015-present ║ Visiting Professor ║ Department o fNeurology, Huashan Hospital, Fudan University (Shanghai, China).
2004-2012 ║ Assistant Professor ║ Depts. of Environmental Medicine and Neurology, University of Rochester (Rochester, New York).
2000-2004 ║ Post-doctoral fellow ║ Dept. of Neurology, Columbia University, New York.
1995-2000 ║ Ph.D ║ Neuroscience, University of Saskatchewan, Canada.
1993-2000 ║ Pharmacist ║ Saskatoon, Canada
1988-1993 ║ BSP ║ Pharmacy, University of Saskatchewan, Canada.
Fellow of the Higher Education Academy, UK
Society for Neuroscience
Society of Toxicology
Roles on external bodies
Invited Scientific Review
A) Journals: Annals of Neurology, Brain, Cell Biology and Toxicology, Cell Death and Disease, European Journal of Pharmacology, Experimental Neurology, Journal of Applied Toxicology, Journal of Neurochemistry, Journal of Neuroscience, Journal of Parkinson’s disease, Mitochondrion, Movement Disorders, Nanomedicine, Nature Communications, Nature Chemical Biology, Naunyn-Schmiedeberg Archives of Pharmacology, Neurobiology of Disease, Neurochemical Research, Neuropharmacology, Neuroscience, Neurotherapeutics, Neurotoxicology, Pharmacology and Therapeutics, PlosOne, Scientific Reports, Toxicological Sciences, Toxicology.
My research interest has always been to study mechanisms of neuronal dysfunction and degeneration as seen in Parkinson’s disease (PD), with the ultimate goal of developing effective therapies for this devastating neurological disorder. The research projects in my lab focus on the following fundamental questions: 1) Is mitochondrial dysfunction pathogenic in PD? If so, can mitochondrial dynamics be targeted for PD treatment? 2) The role of genetic and environmental factors in the development and progression of PD? To address these questions, we perform rigorous biochemical, histological, functional and genetic analyses in experimental models of PD. When applicable, post-mortem human samples are also used.
Grants & contracts
1) MRC ║ £511 K (2014 - 2017) ║ PI: Kim Tieu
2) NIH ║ $740 K (2014 - 2018) ║ PI: Kim Tieu
1) NIH ║ ~ $1,6 M (2006 – 2012) ║ PI: Kim Tieu
2) NIH ║ ~ 422 K (2009 – 2012) ║ PI: Kim Tieu
3) Environmental Protection Agency (EPA) ║ ~ $8 M (2005 – 2010) ║ PI: Gunter Oberdoerster, Kim Tieu: 5% effort
4) NIH ║ $25 K (2005 – 2006) ║ PI: Kim Tieu
Other academic activities
INVITED LECTURES (Past 5 years): 2016 The 5th Oriental Congress of Neurology, Shanghai ║ 2016 Society of Toxicology Annual Meeting, New Orleans ║ 2015 Northeast Ohio Medical University ║ 2015 University of Aberdeen ║ 2015 Universite de Lille, Lille ║ 2015 University of Exeter ║ 2014 Sheffield Institute for Translational Neuroscience, University of Sheffield ║ 2013 University of Oxford, MitOX conference ║ 2013 Cambridge University, John Van Geest Centre for Brain Repair ║ 2013 Vall d'Hebron Research Institute, Barcelona ║ 2013 ASPET Annual Meeting at Experimental Biology, Boston ║ 2012 University of Kansas, Lawrence, Kansas ║ 2011 The XIX World Congress on Parkinson's Disease and Related Disorders, Shanghai ║ 2011 Department of Neurology, Huashan hospital, Fudan University, Shanghai ║ 2011 University of Central Florida, Orlando, Florida ║